New tenant for park
Lamellar Biomedical signs on at Maxim
Maxim Office Park has secured biotechnology company Lamellar Biomedical as a tenant.
Lamellar is taking 3,444 sq ft across suites 1 and 5 within the Maxim 1 building on a five-year lease. Fit-out works are currently under way ahead of its January entry date.
The company, which is relocating from Caledonian House, Bellshill, is developing a range of patent protected medical devices and pharmaceuticals for the healthcare market.
It plans to use its new premises at Maxim to support the further development of its range of medical devices and pharmaceuticals.
Dr Alec McLean, chief executive officer at the company, commented: “Given the range of partnerships that we have developed with NHS Scotland and leading clinicians and academics across the country, this strategic location within easy reach of major Scottish cities and airports will be hugely beneficial to both the business and our staff.”
Craig Ritchie, director at Maxim, added: “Lamellar is the second biotechnology company operating from the Park so it’s fantastic that Maxim is now home to two organisations that are playing a significant role in the Scottish healthcare sector.”
Cushman & Wakefield and Ryden represented Maxim Office Park in both deals, whilst Lamellar Biotechnology was unrepresented.